Brokers Issue Forecasts for Atyr PHARMA FY2026 Earnings

Atyr PHARMA INC (NASDAQ:ATYR) – Equities researchers at HC Wainwright cut their FY2026 earnings estimates for Atyr PHARMA in a research note issued to investors on Tuesday, April 29th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.66) per share for the year, down from their prior estimate of ($0.53). HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Atyr PHARMA’s FY2027 earnings at $0.39 EPS and FY2028 earnings at $0.50 EPS.

A number of other equities research analysts have also recently weighed in on ATYR. Cantor Fitzgerald started coverage on Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating on the stock. Leerink Partners assumed coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price objective on the stock. Finally, Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Atyr PHARMA has an average rating of “Buy” and a consensus target price of $18.60.

Atyr PHARMA Price Performance

NASDAQ:ATYR opened at $3.60 on Friday. Atyr PHARMA has a 12-month low of $1.42 and a 12-month high of $4.66. The firm has a market capitalization of $319.89 million, a price-to-earnings ratio of -3.83 and a beta of 0.95. The stock’s 50 day moving average price is $3.29 and its two-hundred day moving average price is $3.39. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR) last issued its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05.

Hedge Funds Weigh In On Atyr PHARMA

A number of hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its position in shares of Atyr PHARMA by 467.8% during the 4th quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company’s stock worth $646,000 after purchasing an additional 147,092 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in Atyr PHARMA during the fourth quarter worth approximately $144,000. American Century Companies Inc. bought a new position in Atyr PHARMA during the 4th quarter worth $319,000. Victory Capital Management Inc. acquired a new position in Atyr PHARMA in the 4th quarter valued at $37,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Atyr PHARMA during the 4th quarter valued at $39,000. 61.72% of the stock is owned by institutional investors.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.